Literature DB >> 30879160

Importance of m N6-methyladenosine (m6A) RNA modification in cancer.

Gulten Tuncel1, Rasime Kalkan2.   

Abstract

RNA methylation, which was identified back in 1970s, has gained remarkable interest in recent years as it was shown to be a reversible modification involved in many cellular processes like mRNA and miRNA processing, mRNA localisation, translation suppression, or activation. These, in turn, affect important bioprocesses such as tissue development, sex determination, and DNA damage response. Important group of proteins are responsible for adding, recognizing, and removing the methyl group to and from the RNA molecules, which are referred as writers, readers, and erasers, respectively. If any of the processes is not strictly controlled, this can cause abnormalities in gene expression, which result in diseases including cancers such as lung, pancreas, glioblastoma, and breast cancer. Mechanisms of RNA methylation and its role in various cancer types and diagnostic methods for RNA methylation are discussed in this article.

Entities:  

Keywords:  Cancer; Epigenetics; N6-methyladenosine (m6A); RNA methylation

Mesh:

Substances:

Year:  2019        PMID: 30879160     DOI: 10.1007/s12032-019-1260-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  42 in total

1.  Molecular mechanisms of gene silencing mediated by DNA methylation.

Authors:  Michela Curradi; Annalisa Izzo; Gianfranco Badaracco; Nicoletta Landsberger
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

2.  FoxM1: a potential drug target for glioma.

Authors:  Yu Li; Sicong Zhang; Suyun Huang
Journal:  Future Oncol       Date:  2012-03       Impact factor: 3.404

3.  Detection of cytosine methylation in RNA using bisulfite sequencing.

Authors:  Tim Pollex; Katharina Hanna; Matthias Schaefer
Journal:  Cold Spring Harb Protoc       Date:  2010-10-01

Review 4.  Histone methylation: a dynamic mark in health, disease and inheritance.

Authors:  Eric L Greer; Yang Shi
Journal:  Nat Rev Genet       Date:  2012-04-03       Impact factor: 53.242

Review 5.  ADAMs in cancer cell proliferation and progression.

Authors:  Satsuki Mochizuki; Yasunori Okada
Journal:  Cancer Sci       Date:  2007-03-09       Impact factor: 6.716

6.  Widespread occurrence of 5-methylcytosine in human coding and non-coding RNA.

Authors:  Jeffrey E Squires; Hardip R Patel; Marco Nousch; Tennille Sibbritt; David T Humphreys; Brian J Parker; Catherine M Suter; Thomas Preiss
Journal:  Nucleic Acids Res       Date:  2012-02-16       Impact factor: 16.971

7.  N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO.

Authors:  Guifang Jia; Ye Fu; Xu Zhao; Qing Dai; Guanqun Zheng; Ying Yang; Chengqi Yi; Tomas Lindahl; Tao Pan; Yun-Gui Yang; Chuan He
Journal:  Nat Chem Biol       Date:  2011-10-16       Impact factor: 15.040

Review 8.  Post-transcriptional nucleotide modification and alternative folding of RNA.

Authors:  Mark Helm
Journal:  Nucleic Acids Res       Date:  2006-02-01       Impact factor: 16.971

Review 9.  5-methylcytosine in RNA: detection, enzymatic formation and biological functions.

Authors:  Yuri Motorin; Frank Lyko; Mark Helm
Journal:  Nucleic Acids Res       Date:  2009-12-08       Impact factor: 16.971

10.  Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq.

Authors:  Dan Dominissini; Sharon Moshitch-Moshkovitz; Schraga Schwartz; Mali Salmon-Divon; Lior Ungar; Sivan Osenberg; Karen Cesarkas; Jasmine Jacob-Hirsch; Ninette Amariglio; Martin Kupiec; Rotem Sorek; Gideon Rechavi
Journal:  Nature       Date:  2012-04-29       Impact factor: 49.962

View more
  27 in total

1.  FTO overexpression inhibits apoptosis of hypoxia/reoxygenation-treated myocardial cells by regulating m6A modification of Mhrt.

Authors:  Wei Shen; Hongqi Li; Hao Su; Kangyu Chen; Ji Yan
Journal:  Mol Cell Biochem       Date:  2021-02-06       Impact factor: 3.396

2.  m6A demethylase FTO promotes hepatocellular carcinoma tumorigenesis via mediating PKM2 demethylation.

Authors:  Jie Li; Lijun Zhu; Yanhong Shi; Jingnan Liu; Lin Lin; Xi Chen
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

3.  Expression patterns and prognostic value of m6A-related genes in colorectal cancer.

Authors:  Xin Liu; Liwen Liu; Zihui Dong; Jianhao Li; Yan Yu; Xiaolong Chen; Fang Ren; Guangying Cui; Ranran Sun
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

4.  Optimizing cardiac ischemic preconditioning and postconditioning via epitranscriptional regulation.

Authors:  Richa Saxena; Neal L Weintraub; Yaoliang Tang
Journal:  Med Hypotheses       Date:  2019-10-24       Impact factor: 1.538

5.  Identification of pathology-specific regulators of m6A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine.

Authors:  Na Li; Xianquan Zhan
Journal:  EPMA J       Date:  2020-07-29       Impact factor: 6.543

Review 6.  Potential roles of N6-methyladenosine (m6A) in immune cells.

Authors:  Chang Liu; Zhe Yang; Rong Li; Yanju Wu; Ming Chi; Shuting Gao; Xun Sun; Xin Meng; Biao Wang
Journal:  J Transl Med       Date:  2021-06-08       Impact factor: 5.531

7.  Decreased Peripheral Blood ALKBH5 Correlates with Markers of Autoimmune Response in Systemic Lupus Erythematosus.

Authors:  Qing Luo; Biqi Fu; Lu Zhang; Yang Guo; Zikun Huang; Junming Li
Journal:  Dis Markers       Date:  2020-06-25       Impact factor: 3.434

Review 8.  N6-Methyladenosine: A Potential Breakthrough for Human Cancer.

Authors:  Lina Liu; Yuwei Wang; Jie Wu; Jingwen Liu; Zongchang Qin; Hong Fan
Journal:  Mol Ther Nucleic Acids       Date:  2019-12-20       Impact factor: 8.886

Review 9.  The role of miRNA biogenesis and DDX17 in tumorigenesis and cancer stemness.

Authors:  Kou-Juey Wu
Journal:  Biomed J       Date:  2020-04-13       Impact factor: 4.910

10.  Contribution of m6A subtype classification on heterogeneity of sepsis.

Authors:  Shi Zhang; Feng Liu; Zongsheng Wu; Jianfeng Xie; Yi Yang; Haibo Qiu
Journal:  Ann Transl Med       Date:  2020-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.